Therapeutic effect of docetaxel combined with oxaliplatin for treatment of recurrent epithelial ovarian cancer.
- Author:
Jian WANG
1
;
Na HAN
;
Hai-Li WANG
;
Zhong-Mian ZHANG
;
Qing-Xia FAN
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Cystadenoma, Mucinous; drug therapy; Cystadenoma, Serous; drug therapy; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; drug therapy; Organoplatinum Compounds; administration & dosage; Ovarian Neoplasms; drug therapy; Taxoids; administration & dosage
- From: Journal of Southern Medical University 2009;29(11):2319-2320
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) for treatment of recurrent epithelial ovarian cancer.
METHODSThirty-six patients with histologically confirmed recurrent epithelial ovarian cancer received chemotherapy with DTX and OXA. DTX at the dose of 75 mg/m(2) was administered on day 1 by intravenous infusion in 60 min, followed by OXA at 100 mg/m(2) given by a 2 h infusion. The chemotherapy cycles were repeated every 21 days, and the patients received at least 2 cycles.
RESULTSAll the patients were available for response evaluation, among whom 3 (8.3%) showed complete responses and 17 (47.2%) showed partial responses, with an overall response rate of 55.6%. The main adverse effects included hematological toxicities and peripheral neuropathy.
CONCLUSIONCombination of DTX and OXA produces good therapeutic effect with tolerable toxicity profile for treatment of recurrent epithelial ovarian cancer.
